-
In this downloadable slideset, Hossein Borghaei, MS, DO, uses cases to provide insights for the management of patients with progressive advanced NSCLC using immune checkpoint inhibitors.
-
In this slideset, Gary Lyman, MD, MPH, FASCO, discusses the promise and challenges of incorporating oncology biosimilars into clinical practice.
-
In this downloadable slideset, H. Jack West, MD, uses cases to provide insights for the management of patients with newly diagnosed, advanced NSCLC using immune checkpoint inhibitors.
-
In this downloadable slideset, Suresh S, Ramalingam, MD, uses cases to provide insights for the management of patients with advanced NSCLC experiencing toxicities with immune checkpoint inhibitors.
-
In this downloadable slideset, Leena Gandhi, MD, PhD, discusses emerging directions in the use of immune checkpoint inhibitors for advanced NSCLC.
|
Latest Content
-
In this downloadable slideset, John L. Marshall, MD, reviews the latest clinical data on biomarkers of response to immune checkpoint inhibitors in CRC. These slides accompany the CME-certified Clinical Focus module comprising Dr. Marshall’s expert in-depth discussion.
Date Posted: 6/21/2017
-
In this module, John L. Marshall, MD, reviews practice-changing immunotherapy options for patients with metastatic colorectal cancer, as well as biomarkers that predict response to immune checkpoint inhibitors and the latest data supporting their use in GI malignancies.
Faculty: John L. Marshall MD
Released: 6/21/2017
-
| Tanios Bekaii-Saab MD, FACP - 6/21/2017 |
1 comment / Last Comment: 6/21/2017 |
With the first immunotherapy agent approved for use in colorectal cancer, how is this going to change your practice?
-
Results of this large international phase III trial showed that denosumab was associated with significantly less renal toxicity and prolonged PFS vs zoledronic acid in patients with newly diagnosed MM.
Date Posted: 6/14/2017
-
In patients with advanced urothelial carcinoma, epacadostat plus pembrolizumab well tolerated, with ORR of 35% (DCR: 53%) in this patient cohort.
Date Posted: 6/14/2017
-
In these subanalyses of the CALGB/SWOG 80405 trial, tumor sidedness was a prognostic factor independent of other molecular features, and BRAF status was also a strong prognostic marker for patients with mCRC receiving first-line treatment.
Date Posted: 6/14/2017
-
Pembrolizumab well tolerated, produced durable responses in patients with pretreated, advanced gastric/GEJ cancer, with highest responses in PD-L1–positive subgroup.
Date Posted: 6/13/2017
-
Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden.
Date Posted: 6/12/2017
-
In this downloadable slideset, Hossein Borghaei, MS, DO, uses cases to provide insights for the management of patients with progressive advanced NSCLC using immune checkpoint inhibitors.
Date Posted: 6/9/2017
-
In this slideset, Rowena Schwartz, PharmD, BCOP, discusses the regulatory standards and benchmarks necessary for the approval of therapeutic biosimilars.
Date Posted: 6/9/2017
|
|
|